Biocon, Asia’s largest biotech company, and CytoSorbents Corporation, based in the United States, have entered into a strategic partnership with an initial distribution agreement for India and select emerging markets, under which Biocon will have the exclusive commercialization rights for CytoSorb, a novel therapy for the management of sepsis.
Biocon and CytoSorbents will initially focus on the treatment of sepsis - the end result of an excessive immune response to infection. The effective treatment of sepsis needs to address two components - the infection and the over-activation of the immune system. By combining Biocon’s critical care antibiotics to treat the infection that are also compatible with CytoSorb therapy to modulate the immune response, the two companies will be providing the most comprehensive solution for sepsis management in the market.
CytoSorb is a safe and effective extracorporeal cytokine filter, designed to target the prevention or treatment of organ failure which is the cause of nearly half of all deaths in the intensive care unit. CytoSorb has CE Mark regulatory approval, and is clinically proven to control cytokine storm in critically-ill patients by reducing key cytokines in blood by 30-50%. It also works easily with standard dialysis machines used in hospitals.
